Table 4. Results from meta-analysis of IL-18 gene promoter haplotypes.
−607A/−137C vs. −607C/−137G | −607A/−137G vs. −607C/−137G | −607C/−137C vs. −607C/−137G | |||||
N | OR | Ph | OR | Ph | OR | Ph | |
Total | 26 | 1.08(0.97, 1.21) | <0.001 | 1.01(0.95, 1.08) | <0.001 | 1.04(0.93, 1.17) | <0.001 |
Cancer Types | |||||||
GC | 6 | 1.13(0.76, 1.68) | <0.001 | 1.07(0.79, 1.45) | <0.001 | 1.00(0.86, 1.17) | 0.389 |
NC | 4 | 1.26(1.13, 1.40)* | 0.569 | 1.05(0.96, 1.16) | 0.951 | 1.14(1.03, 1.27)* | 0.775 |
GUC | 4 | 0.99(0.83, 1.19) | 0.008 | 0.97(0.90, 1.04) | 0.631 | 1.06(0.92, 1.21) | 0.051 |
GIC | 6 | 1.17(0.94, 1.47) | <0.001 | 0.99(0.85, 1.14) | 0.001 | 1.16(0.84, 1.59) | <0.001 |
BC | 2 | 0.98(0.76, 1.27) | 0.242 | 1.09(0.93, 1.27) | 0.570 | 0.88(0.74, 1.04) | 0.454 |
Others | 4 | 0.87(0.56, 1.37) | <0.001 | 1.05(0.91, 1.20) | 0.537 | 0.83(0.60, 1.17) | 0.006 |
Ethnicities | |||||||
Asian | 18 | 1.12(0.99, 1.26) | <0.001 | 1.03(0.96, 1.11) | 0.006 | 1.06(0.98, 1.14) | 0.044 |
Caucasian | 6 | 0.98(0.69, 1.38) | <0.001 | 0.95(0.82, 1.11) | 0.018 | 0.98(0.64, 1.49) | <0.001 |
African | 1 | 1.11(0.88, 1.38) | NA | 1.03(0.84, 1.25) | NA | 1.05(0.85, 1.31) | NA |
Mixed | 1 | 0.81(0.56, 1.15) | NA | 1.00(0.80, 1.24) | NA | 0.81(0.56, 1.15) | NA |
Source of Controls | |||||||
PB | 16 | 0.97(0.83, 1.14) | <0.001 | 0.98(0.90,1.06) | 0.003 | 0.98(0.82, 1.18) | <0.001 |
HB | 10 | 1.25(1.10, 1.42)* | 0.003 | 1.06(0.96, 1.18) | 0.006 | 1.15(1.07, 1.23)* | 0.487 |
Sample Size | |||||||
Large a | 4 | 1.06(0.84, 1.34) | <0.001 | 1.01(0.94, 1.08) | 0.627 | 1.05(0.92, 1.21) | 0.056 |
Small b | 22 | 1.09(0.96, 1.24) | <0.001 | 1.02(0.94, 1.10) | <0.001 | 1.04(0.90, 1.19) | <0.001 |
GC: Gynecological cancer; NC: Nasopharyngeal carcinoma; GUC: Genitourinary system cancer; GIC: Gastrointestinal cancer; BC: Breast cancer; N: number of studies included; OR: odds ratio; Ph: p value for heterogeneity;
OR with statistical significance;
studies with more than 500 participants;
studies with less than 500 participants;